Abstract:Background Hypoxia-inducible factor-1α (HIF-1α), a critical transcription factor to reduced O 2 availability, has been demonstrated to be extensively involved in tumor survival, aggressive progression, drug resistance and angiogenesis. Thus it has been considered as a potential anticancer target. Triptolide is the main principle responsible for the biological activities of the Traditional Chinese Medicine tripterygium wilfordii Hook F. Triptolide possesses great chemotherapy potential for cancer with its broad-spectrum anticancer, antiangiogenesis, and drug-resistance circumvention activities. Numerous biological molecules inhibited by triptolide have been viewed as its possible targets. However, the anticancer action mechanisms of triptolide remains to be further investigated. Here we used human ovarian SKOV-3 cancer cells as a model to probe the effect of triptolide on HIF-1α. Results Triptolide was observed to inhibit the proliferation of SKOV-3 cells, and meanwhile, to enhance the accumulation of HIF-1α protein in SKOV-3, A549 and DU145 cells under different conditions. Triptolide did not change the kinetics or nuclear localization of HIF-1α protein or the 26 S proteasome activity in SKOV-3 cells. However, triptolide was found to increase the levels of HIF-1α mRNA. Unexpectedly, the HIF-1α protein induced by triptolide appeared to lose its transcriptional activity, as evidenced by the decreased mRNA levels of its target genes including VEGF, BNIP3 and CAIX. The results were further strengthened by the lowered secretion of VEGF protein, the reduced sprout outgrowth from the rat aorta rings and the inhibitory expression of the hypoxia responsive element-driven luciferase reporter gene. Moreover, the silencing of HIF-1α partially prevented the cytotoxicity and apoptosis triggered by triptolide. Conclusions The potent induction of HIF-1α protein involved in its cytotoxicity, together with the suppression of HIF-1 transcriptional activity, indicates the great therapeutic potential of triptolide as an anticancer drug. Meanwhile, our data further stress the possibility that HIF-1α functions in an unresolved nature or condition.

Triptolide Inhibits MCF‐7 Cell Growth Via Estrogen Receptor‐α‐related Pathways (657.5)

Triptolide-induced in vitro and in vivo cytotoxicity in human breast cancer stem cells and primary breast cancer cells.

Triptolide suppresses melanoma cell growth in vitro and in vivo through the Src-ERK signaling pathway

[Effect of Triptolide on Human Oral Cancer Cell Proliferation and PTEN Gene Mrna Expression in Oral Cancer].

Triptolide prevents proliferation and migration of Esophageal Squamous Cell Cancer via MAPK/ERK signaling pathway

Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/β-catenin signaling pathway in taxol-resistant human lung adenocarcinoma

Triptolide Induces Growth Inhibition And Apoptosis Of Human Laryngocarcinoma Cells By Enhancing P53 Activities And Suppressing E6-Mediated P53 Degradation

Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells

Data from Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II

Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway

Triptolide induces apoptosis through the calcium/calmodulin‑dependent protein kinase kinaseβ/AMP‑activated protein kinase signaling pathway in non‑small cell lung cancer cells.

Triptolide Inhibits the Growth of Osteosarcoma by Regulating Microrna-181A Via Targeting PTEN Gene in Vivo and Vitro.

Triptolide Inhibits Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression in Human Colon Cancer and Leukemia Cells

Triptolide Inhibits Tumor Growth by Induction of Cellular Senescence.

Potential antitumor activity of triptolide and its derivatives: Focused on gynecological and breast cancers

Triptolide Inhibits Vascular Endothelial Growth Factor Expression and Production in Endothelial Cells.

Broad targeting of triptolide to resistance and sensitization for cancer therapy

Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression

Increased Accumulation of Hypoxia-Inducible Factor-1Α with Reduced Transcriptional Activity Mediates the Antitumor Effect of Triptolide.

Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial–mesenchymal transition

Triptonide inhibits growth and metastasis in HCC by suppressing EGFR/PI3K/AKT signaling